YOLFTbeta
Knight Therapeutics Inc.

Knight Therapeutics Inc.

GUD · TO · Healthcare / Drug Manufacturers - Specialty & Generic

12.06CAD+0.01 (+0.08%)

Price History

Full chart

Market Stats

Previous Close12.05
Open12.10
Day Range11.89 – 12.19
52-Week Range5.66 – 10.80
Volume45.52K
Market Cap1.01B
P/E (TTM)68.80
Forward P/E35.46
EPS0.15
Dividend Yield0.00%
Beta0.04
50-Day Avg9.83
200-Day Avg8.02

About

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMs. Samira Sakhia BCom, CA, CPA, MBA
  • Employees830
  • Headquarters100 Boul. Alexis-Nihon, Montreal, QC, Canada, H4M 2P2, Canada
  • Websitehttps://www.knighttx.com

Leadership

  • Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A.Executive Chairman · b. 1969
  • Ms. Samira Sakhia BCom, CA, CPA, MBAPresident, CEO & Director · b. 1968
  • Mr. Arvind UtchanahChief Financial Officer
  • Mr. Leopoldo BosanoVice-President of Manufacturing & Operations
  • Ms. Susan Caroline EmblemGlobal Vice President of Human Resources
  • Ms. Amal Khouri B.Sc., M.B.A.Chief Business Officer
  • Ms. Christine PoulinGeneral Manager of Canada
  • Ms. Monica PercarioGlobal Vice President of Regulatory & Quality
  • Mr. Henrique DiasGlobal Vice President of Marketing
  • Ms. Melanie GroleauGlobal Vice President of Medical & Clinical

Financials

Income Statement

Currency: CAD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue365.32K1.04M5.94M8.63M12.50M47.46M199.52M243.48M293.56M328.20M371.30M450.09M
Growth (%)-+183.86%+472.81%+45.35%+44.78%+279.69%+320.39%+22.03%+20.57%+11.80%+13.13%+21.22%
Cost of Revenue-428.00K1.55M1.58M2.31M20.54M117.83M128.07M155.50M175.55M196.90M299.35M
Gross Profit365.32K609.00K4.39M7.05M10.20M26.92M81.69M115.41M138.06M152.65M174.41M150.74M
Gross Margin100.00%58.73%73.91%81.64%81.56%56.72%40.94%47.40%47.03%46.51%46.97%33.49%
Operating Expense5.40M11.92M12.23M15.96M15.98M12.93M85.13M120.73M140.46M155.54M167.01M152.94M
Operating Income-5.03M-11.31M-7.84M-8.91M-5.78M13.99M-3.44M-5.32M-2.40M-2.89M7.40M-2.20M
Operating Margin-1377.36%-1090.45%-131.92%-103.15%-46.26%29.47%-1.72%-2.19%-0.82%-0.88%1.99%-0.49%
EBITDA131.16M-11.18M-7.40M-7.28M-3.85M27.16M67.56M42.59M25.26M40.90M64.38M54.37M
EBITDA Margin35903.12%-1078.50%-124.56%-84.28%-30.81%57.23%33.86%17.49%8.60%12.46%17.34%12.08%
Net Income125.86M34.17M18.56M17.24M24.08M14.52M31.76M15.68M-29.89M-16.84M4.33M-5.37M
Net Income Margin34451.40%3294.79%312.46%199.72%192.63%30.59%15.92%6.44%-10.18%-5.13%1.17%-1.19%
R&D1.03M2.71M1.96M2.75M1.99M3.91M11.72M12.69M14.76M17.55M23.30M28.98M
R&D as % of Total Revenue281.54%261.04%32.91%31.85%15.93%8.24%5.88%5.21%5.03%5.35%6.28%6.44%
Interest Expense23.54K18.63M24.41M26.30M20.93M370.00K3.40M3.62M6.60M12.49M9.22M10.42M
Interest Expense % of Total Revenue6.44%1796.72%411.01%304.61%167.47%0.78%1.70%1.49%2.25%3.81%2.48%2.32%

Balance Sheet

Currency: CAD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1486.61M648.99M990.77M1.01B1.05B1.31B1.04B991.89M1.05B945.49M963.80M1.05B
Total Liabilities-7.62M6.93M11.05M14.78M21.80M390.20M153.44M149.87M228.98M198.62M168.69M279.03M
Total Equity1478.99M642.06M979.72M991.21M1.03B810.73M886.24M842.02M825.86M746.87M795.11M767.27M
Cash1283.45M237.48M514.94M496.46M244.78M169.27M229.59M85.96M71.68M58.76M80.11M76.45M
Total Debt------62.18M56.19M40.96M77.70M69.09M49.46M77.91M
Net Debt-1-283.45M-237.48M-514.94M-496.46M-244.78M-107.09M-173.40M-45.01M6.02M10.33M-30.65M1.46M

Cash Flow

Currency: CAD2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow803.34K7.64M14.74M23.46M-5.74M4.60M-12.21M44.62M40.48M35.94M36.28M70.30M
Investing Cash Flow-49.09M-67.08M-49.22M-39.99M-252.31M-11.86M101.35M-105.28M-63.08M29.34M16.96M-84.11M
Financing Cash Flow328.72M13.86M313.33M746.00K290.00K-62.80M-29.23M-78.31M1.76M-81.00M-33.54M13.01M
Capital Expenditure69.68K1.75M9.86M126.00K3.87M2.95M20.67M224.18M25.82M9.96M31.47M1.91M
Free Cash Flow733.66K5.89M4.88M23.33M-9.61M1.65M-32.87M-179.56M14.66M25.98M4.81M68.40M
Dividends Paid247.75M-------0000
FCF to OCF91.33%77.08%33.10%99.46%167.47%35.86%269.34%-402.45%36.23%72.29%13.25%97.29%
Dividend Paid to FCF33769.06%-------0.00%0.00%0.00%0.00%

Earnings

Report DateMay 28, 2014Aug 14, 2014Nov 12, 2014Mar 19, 2015May 13, 2015Aug 12, 2015Nov 11, 2015Mar 24, 2016May 10, 2016Aug 11, 2016Nov 10, 2016Mar 16, 2017May 11, 2017Aug 10, 2017Nov 9, 2017Mar 15, 2018May 10, 2018Aug 9, 2018Nov 8, 2018Mar 14, 2019May 9, 2019Aug 8, 2019Nov 12, 2019Mar 30, 2020Jun 26, 2020Aug 13, 2020Nov 13, 2020Mar 25, 2021May 14, 2021Aug 13, 2021Nov 11, 2021Mar 24, 2022May 12, 2022Aug 11, 2022Nov 10, 2022Mar 23, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 21, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Mar 19, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Mar 19, 2026May 6, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate------0.01-0.020.04-0.010.020.040.030.030.020.040.020.030.030.030.030.020.020.04-0.060.050.010.010.04-0.070.02--0.040.080.01-0.080.060.03-0.05-0.02-0.010.030.020.01-0.010.020.020.010.010.030.01
EPS Actual-0.010.010.01-0.020.020.020.070.050.010.040.040.060.040.010.050.050.030.030.100.000.040.13-0.020.04-0.010.080.050.060.050.23-0.07-0.07-0.160.090.08-0.13-0.040.020.09-0.23-0.04-0.020.000.110.03-0.09-0.010.100.14-0.03-
Surprise-----300.00%-150.00%-75.00%500.00%100.00%50.00%33.33%-66.67%150.00%25.00%50.00%0.00%233.33%-95.00%33.33%550.00%-200.00%0.00%83.33%60.00%400.00%500.00%25.00%428.57%-450.00%--300.00%12.50%700.00%-62.50%-166.67%-33.33%280.00%-1050.00%-300.00%-166.67%-96.00%973.00%400.00%-550.00%-150.00%900.00%1289.00%-200.00%-
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap1.01B
Enterprise Value904.26M
Trailing P/E68.80
Forward P/E35.46
Price / Sales1.85
Price / Book1.24
EPS0.15
Book Value8.13
Revenue (TTM)547.31M
Gross Profit (TTM)259.26M
EBITDA81.16M
Profit Margin2.72%
Operating Margin6.21%
Return on Equity1.91%
Return on Assets1.32%
Shares Outstanding98.23M
Shares Float60.60M
Beta0.04
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%